Kelly Jason R reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. granted Chief Executive Officer and founder Jason R. Kelly two awards of restricted stock units on July 28, 2026. One grant covers 74,258 RSUs vesting 75% on October 16, 2026 and 25% on January 21, 2027. The other grant covers 309,467 RSUs vesting in equal quarterly installments over 12 quarters starting October 16, 2026. Each RSU represents a contingent right to receive one share of Class A Common Stock.
Ginkgo Bioworks Holdings, Inc. plans to host a presentation and Q&A session reviewing its business performance for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, beginning at 4:30 p.m. ET.
The session will be webcast via Ginkgo's investor relations website, with a replay available. Shareholders may submit questions in advance via X to @Ginkgo using hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com. The company highlights its websites, blog, news site, and social media channels as outlets for potentially material information.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A stock. BlackRock’s reporting business units collectively beneficially own 4,122,510 shares, representing 7.7% of the Class A shares outstanding. They hold sole voting power over 4,013,128 shares and sole dispositive power over 4,122,510 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client’s interest exceeds five percent of Ginkgo Bioworks’ outstanding common shares. The position is reported by BlackRock as a parent holding company through relevant subsidiaries identified in an exhibit, and the filing is signed by Managing Director Spencer Fleming.
Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen reported RSU vesting and related share movements. On July 16, 2026, 1,486 restricted stock units converted into Class A Common Stock. On July 17, 2026, he sold 752 shares at $7.903 per share to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement.
Ginkgo Bioworks Holdings, Inc. insider Steve Coen filed to sell Class A common stock under a planned transaction. The notice lists 752 Class A shares to be sold through Fidelity Brokerage Services on the NYSE and identifies the shares as originating from restricted stock vesting used as compensation. It also reports prior Class A stock sales over the last three months.
HENRY CHRISTIAN O reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Henry Christian O reported receiving a grant of 25,000 restricted stock units. Each RSU represents a contingent right to receive one share of Class A common stock. The award vests on the earlier of June 11, 2027 or the day before the next annual meeting, if he continues serving as a non-employee director. Following this grant, his reported RSU holdings from this award total 25,000 units.
Ginkgo Bioworks Holdings, Inc. reported that director Ross Fubini received a grant of 25,000 Restricted Stock Units on June 11, 2026. Each RSU represents a contingent right to one share of Class A common stock, with no cash exercise price.
The RSUs vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date, subject to Fubini continuing to serve as a non-employee director through the vesting date. Following this award, his directly held RSUs from this grant total 25,000 units.
Kosuri Sri reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Sri Kosuri received a grant of 25,000 restricted stock units on June 11, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of the company’s Class A common stock. The RSUs will vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date, provided Kosuri continues to serve as a non-employee director through that vesting date. This is a stock-based award, not an open-market share purchase or sale.
SLOAN HARRY reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Harry Sloan received a grant of 25,000 restricted stock units on June 11, 2026. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest on the earlier of June 11, 2027 or the day before the next annual meeting, if he continues serving as a non-employee director.
Austin Che reported proposed sales of Class A shares under Form 144, listing multiple sale notifications through a Fidelity Brokerage Services LLC account. Reported sale entries include 2,200 shares on 03/11/2026 for $13,882 and 40,893 shares on 04/13/2026 for $262,291.79, plus additional smaller dated entries.